Caterpillar bids for Australia’s RPMGlobal- AFR
Investing.com - RBC Capital has raised its price target on Natera (NASDAQ:NTRA) to $255.00 from $251.00 while maintaining an Outperform rating on the stock. The company, currently valued at $22.34 billion, has demonstrated impressive revenue growth of 51.5% over the last twelve months, according to InvestingPro data.
The price target adjustment follows what RBC Capital described as "another noteworthy quarter" for the liquid biopsy company, with strength demonstrated across all categories. The company maintains a healthy financial position with a current ratio of 3.87 and a strong gross profit margin of 61.79%.
RBC Capital highlighted particular strength in Signatera volume and average selling prices (ASPs), which contributed to significant revenue outperformance and a subsequent guidance raise by the company. While InvestingPro analysis suggests the stock is currently trading above its Fair Value, the company maintains a "GREAT" overall financial health score.
The investment firm stated that Natera remains its "favorite liquid biopsy idea" and suggested that the company continues to command a premium multiple due to the scarcity of high-growth names in the healthcare sector.
RBC Capital also noted that Natera has multiple "shots on goal" across near, medium, and long-term timeframes, though specific details about these opportunities were not elaborated upon.
In other recent news, Natera reported its second-quarter 2025 earnings, showcasing a mixed financial performance. The company achieved a revenue of $546.6 million, exceeding forecasts by 14.85%, although its earnings per share (EPS) fell short of expectations at -$0.74 compared to the anticipated -$0.62. Despite the EPS miss, the strong revenue growth led to a positive market reaction. Bernstein SocGen Group raised its price target for Natera to $205, citing the impressive revenue figures, while maintaining an Outperform rating. Similarly, TD Cowen increased its price target to $215 from $200, highlighting the company’s robust performance across key metrics and maintaining a Buy rating. These developments reflect the positive sentiment among analysts regarding Natera’s recent achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.